Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

The nose is an organ too.

Mukhtyar C, Mills J, Scott DGI.

Rheumatology (Oxford). 2020 Mar 2. pii: keaa073. doi: 10.1093/rheumatology/keaa073. [Epub ahead of print] No abstract available.

PMID:
32118271
2.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines.

Tieu J, Smith R, Basu N, Brogan P, D'Cruz D, Dhaun N, Flossmann O, Harper L, Jones RB, Lanyon PC, Luqmani RA, McAdoo SP, Mukhtyar C, Pearce FA, Pusey CD, Robson JC, Salama AD, Smyth L, Watts RA, Willcocks LC, Jayne DRW.

Rheumatology (Oxford). 2020 Apr 1;59(4):e24-e32. doi: 10.1093/rheumatology/kez640. No abstract available.

PMID:
32096545
3.

Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary.

Tieu J, Smith R, Basu N, Brogan P, D'Cruz D, Dhaun N, Flossmann O, Harper L, Jones RB, Lanyon PC, Luqmani RA, McAdoo SP, Mukhtyar C, Pearce FA, Pusey CD, Robson JC, Salama AD, Smyth L, Watts RA, Willcocks LC, Jayne DRW.

Rheumatology (Oxford). 2020 Apr 1;59(4):727-731. doi: 10.1093/rheumatology/kez632. No abstract available.

PMID:
32096542
4.

Feasibility and face validity of outcome measures for use in future studies of Polymyalgia Rheumatica (PMR): An OMERACT Study.

Yates M, Owen CE, Muller S, Graham K, Neill L, Twohig H, Boers M, Pujades-Rodriguez M, Goodman S, Cheah J, Dejaco C, Mukhtyar C, Nielsen BD, Robson J, Simon LS, Shea B, Mackie SL, Hill CL; OMERACT PMR Working Group.

J Rheumatol. 2020 Feb 1. pii: jrheum.190575. doi: 10.3899/jrheum.190575. [Epub ahead of print]

PMID:
32007937
5.

British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary.

Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B.

Rheumatology (Oxford). 2020 Mar 1;59(3):487-494. doi: 10.1093/rheumatology/kez664. No abstract available.

PMID:
31970410
6.

British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis.

Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B.

Rheumatology (Oxford). 2020 Mar 1;59(3):e1-e23. doi: 10.1093/rheumatology/kez672. No abstract available.

PMID:
31970405
7.

The need to establish standards of care for Giant Cell Arteritis.

Mukhtyar C, Hodgson H.

Rheumatology (Oxford). 2020 Apr 1;59(4):702-704. doi: 10.1093/rheumatology/kez548. No abstract available.

PMID:
31764974
8.

Validating a diagnostic GCA ultrasonography service against temporal artery biopsy and long-term clinical outcomes.

Mukhtyar C, Myers H, Scott DGI, Misra A, Jones C.

Clin Rheumatol. 2019 Oct 1. doi: 10.1007/s10067-019-04772-2. [Epub ahead of print]

PMID:
31576487
9.

Development of an evidence-based regimen of prednisolone to treat giant cell arteritis - the Norwich regimen.

Mukhtyar C, Cate H, Graham C, Merry P, Mills K, Misra A, Jones C.

Rheumatol Adv Pract. 2019 Feb 1;3(1):rkz001. doi: 10.1093/rap/rkz001. eCollection 2019.

10.

Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases.

Wijetilleka S, Jayne D, Mukhtyar C, Karim MY.

Lupus Sci Med. 2019 Jul 30;6(1):e000337. doi: 10.1136/lupus-2019-000337. eCollection 2019.

11.

Pattern recognition is a sequential process-accurate diagnosis and treatment 20 years after presentation.

Merinopoulos D, Saada J, Jones C, Mukhtyar C.

Oxf Med Case Reports. 2019 Jul 5;2019(7):omz058. doi: 10.1093/omcr/omz058. eCollection 2019 Jul.

12.

2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, Cassie R, Cid MC, Dasgupta B, Dejaco C, Hatemi G, Hollinger N, Mahr A, Mollan SP, Mukhtyar C, Ponte C, Salvarani C, Sivakumar R, Tian X, Tomasson G, Turesson C, Schmidt W, Villiger PM, Watts R, Young C, Luqmani RA.

Ann Rheum Dis. 2020 Jan;79(1):19-30. doi: 10.1136/annrheumdis-2019-215672. Epub 2019 Jul 3.

PMID:
31270110
13.

Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review.

Wijetilleka S, Mukhtyar C, Jayne D, Ala A, Bright P, Chinoy H, Harper L, Kazmi M, Kiani-Alikhan S, Li C, Misbah S, Oni L, Price-Kuehne F, Salama A, Workman S, Wrench D, Karim MY.

Autoimmun Rev. 2019 May;18(5):535-541. doi: 10.1016/j.autrev.2019.03.010. Epub 2019 Mar 4.

PMID:
30844552
14.

Re: 'ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies' by Mikulska et al.

Wijetilleka S, Jayne D, Mukhtyar C, Karim MY.

Clin Microbiol Infect. 2019 Apr;25(4):531-532. doi: 10.1016/j.cmi.2018.12.025. Epub 2018 Dec 27. No abstract available.

15.

Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases.

Wijetilleka S, Jayne DR, Mukhtyar C, Ala A, Bright PD, Chinoy H, Harper L, Kazmi MA, Kiani-Alikhan S, Li CK, Misbah SA, Oni L, Price-Kuehne FE, Salama AD, Workman S, Wrench D, Karim MY.

Rheumatology (Oxford). 2019 May 1;58(5):889-896. doi: 10.1093/rheumatology/key394.

PMID:
30590695
16.

Giant cell arteritis: new concepts, treatments and the unmet need that remains.

Coath F, Gillbert K, Griffiths B, Hall F, Kay L, Lanyon P, Luqmani R, Mackie SL, Mason JC, Mills J, Mollan S, Morgan AW, Mukhtyar C, Quick V, Watts R, Dasgupta B.

Rheumatology (Oxford). 2019 Jul 1;58(7):1316. doi: 10.1093/rheumatology/key411. No abstract available.

PMID:
30544209
17.

Conventional and biological immunosuppressants in vasculitis.

Guillevin L, Mukhtyar C, Pagnoux C, Yates M.

Best Pract Res Clin Rheumatol. 2018 Feb;32(1):94-111. doi: 10.1016/j.berh.2018.07.006. Epub 2018 Aug 22. Review.

PMID:
30526901
18.

Giant cell arteritis: new concepts, treatments and the unmet need that remains.

Coath F, Gillbert K, Griffiths B, Hall F, Kay L, Lanyon P, Luqmani R, Mackie SL, Mason JC, Mills J, Mollan S, Morgan AW, Mukhtyar C, Quick V, Watts R, Dasgupta B.

Rheumatology (Oxford). 2019 Jul 1;58(7):1123-1125. doi: 10.1093/rheumatology/key326. No abstract available. Erratum in: Rheumatology (Oxford). 2019 Jul 1;58(7):1316.

19.

Assessing Vasculitis in Giant Cell Arteritis by Ultrasound: Results of OMERACT Patient-based Reliability Exercises.

Schäfer VS, Chrysidis S, Dejaco C, Duftner C, Iagnocco A, Bruyn GA, Carrara G, D'Agostino MA, De Miguel E, Diamantopoulos AP, Fredberg U, Hartung W, Hocevar A, Juche A, Kermani TA, Koster MJ, Lorenzen T, Macchioni P, Milchert M, Døhn UM, Mukhtyar C, Ponte C, Ramiro S, Scirè CA, Terslev L, Warrington KJ, Dasgupta B, Schmidt WA.

J Rheumatol. 2018 Aug;45(9):1289-1295. doi: 10.3899/jrheum.171428. Epub 2018 Jul 1.

PMID:
29961687
20.

Definitions and reliability assessment of elementary ultrasound lesions in giant cell arteritis: a study from the OMERACT Large Vessel Vasculitis Ultrasound Working Group.

Chrysidis S, Duftner C, Dejaco C, Schäfer VS, Ramiro S, Carrara G, Scirè CA, Hocevar A, Diamantopoulos AP, Iagnocco A, Mukhtyar C, Ponte C, Naredo E, De Miguel E, Bruyn GA, Warrington KJ, Terslev L, Milchert M, D'Agostino MA, Koster MJ, Rastalsky N, Hanova P, Macchioni P, Kermani TA, Lorenzen T, Døhn UM, Fredberg U, Hartung W, Dasgupta B, Schmidt WA.

RMD Open. 2018 May 17;4(1):e000598. doi: 10.1136/rmdopen-2017-000598. eCollection 2018.

21.

Why subcutaneous methotrexate should be a prerequisite to biologic use in patients with rheumatoid arthritis.

Koduri GM, Mukhtyar C.

Rheumatology (Oxford). 2019 Apr 1;58(4):559-560. doi: 10.1093/rheumatology/key097. No abstract available.

PMID:
29672739
22.

Are PR3 positive and MPO positive GPA the same disease?

Fordham S, Mukhtyar C.

Int J Rheum Dis. 2019 Jan;22 Suppl 1:86-89. doi: 10.1111/1756-185X.13278. Epub 2018 Apr 3. Review.

PMID:
29611345
23.

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts.

Yates M, Watts R, Bajema I, Cid M, Crestani B, Hauser T, Hellmich B, Holle J, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel P, Mills J, Mooney J, Segelmark M, Tesar V, Westman KWA, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

RMD Open. 2017 Jun 15;3(1):e000449. doi: 10.1136/rmdopen-2017-000449. eCollection 2017.

24.

The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica.

Mackie SL, Twohig H, Neill LM, Harrison E, Shea B, Black RJ, Kermani TA, Merkel PA, Mallen CD, Buttgereit F, Mukhtyar C, Simon LS, Hill CL; OMERACT PMR Working Group.

J Rheumatol. 2017 Oct;44(10):1515-1521. doi: 10.3899/jrheum.161109. Epub 2017 Aug 1.

25.

Response to: 'Renal biopsies should be performed whenever treatment strategies depend on renal involvement' by Chemouny et al.

Yates M, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2017 Aug;76(8):e28. doi: 10.1136/annrheumdis-2016-210962. Epub 2017 Jan 25. No abstract available.

PMID:
28122763
26.

How to treat ANCA‑associated vasculitis: practical messages from 2016 EULAR/ERA‑EDTA recommendations.

Sznajd J, Mukhtyar C.

Pol Arch Med Wewn. 2016 Oct 28;126(10):781-788. doi: 10.20452/pamw.3598. Epub 2016 Oct 28. Review.

27.

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, Hellmich B, Holle JU, Laudien M, Little MA, Luqmani RA, Mahr A, Merkel PA, Mills J, Mooney J, Segelmark M, Tesar V, Westman K, Vaglio A, Yalçındağ N, Jayne DR, Mukhtyar C.

Ann Rheum Dis. 2016 Sep;75(9):1583-94. doi: 10.1136/annrheumdis-2016-209133. Epub 2016 Jun 23. Erratum in: Ann Rheum Dis. 2017 Aug;76(8):1480.

28.

Behçet's pulmonary artery aneurysms treated with infliximab and monitored with the 6-min walk test.

Kotecha J, Kamath AV, Mukhtyar C.

Oxf Med Case Reports. 2016 Apr 26;2016(4):94-6. doi: 10.1093/omcr/omw028. eCollection 2016 Apr.

29.

Revising DAS28 scores for remission in rheumatoid arthritis.

Sheehy C, Evans V, Hasthorpe H, Mukhtyar C.

Clin Rheumatol. 2014 Feb;33(2):269-72. doi: 10.1007/s10067-013-2468-z. Epub 2014 Jan 3.

PMID:
24384827
30.

Standardized grip strength as an outcome measure in early rheumatoid arthritis.

Sheehy C, Gaffney K, Mukhtyar C.

Scand J Rheumatol. 2013;42(4):289-93. doi: 10.3109/03009742.2012.747624. Epub 2013 Jan 14.

PMID:
23311733
31.

Disseminated Mycobacterium avium infection masquerading as longstanding polymyositis.

Shipman AR, Levell NJ, Afridi KS, Hutchinson R, Lucas S, Murphy J, Phillips R, Mukhtyar C.

JRSM Short Rep. 2011 Dec;2(12):94. doi: 10.1258/shorts.2011.011091. Epub 2011 Dec 6. No abstract available.

32.

Isolated large vessel pulmonary vasculitis as a cause of chronic obstruction of the pulmonary arteries.

Hagan G, Gopalan D, Church C, Rassl D, Mukhtyar C, Wistow T, Lang C, Sivasothy P, Stewart S, Jayne D, Sheares K, Tsui S, Jenkins DP, Pepke-Zaba J.

Pulm Circ. 2011 Jul-Sep;1(3):425-9. doi: 10.4103/2045-8932.87312.

33.

A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis.

Suppiah R, Judge A, Batra R, Flossmann O, Harper L, Höglund P, Javaid MK, Jayne D, Mukhtyar C, Westman K, Davis JC Jr, Hoffman GS, McCune WJ, Merkel PA, St Clair EW, Seo P, Spiera R, Stone JH, Luqmani R.

Arthritis Care Res (Hoboken). 2011 Apr;63(4):588-96. doi: 10.1002/acr.20433.

34.

Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis.

Walsh M, Mukhtyar C, Mahr A, Herlyn K, Luqmani R, Merkel PA, Jayne DR.

Arthritis Care Res (Hoboken). 2011 Jul;63(7):1055-61. doi: 10.1002/acr.20471.

35.

A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis.

Suppiah R, Mukhtyar C, Flossmann O, Alberici F, Baslund B, Batra R, Brown D, Holle J, Hruskova Z, Jayne DR, Judge A, Little MA, Palmisano A, Stegeman C, Tesar V, Vaglio A, Westman K, Luqmani R.

Rheumatology (Oxford). 2011 May;50(5):899-905. doi: 10.1093/rheumatology/keq400. Epub 2010 Dec 13.

36.

Long-term patient survival in ANCA-associated vasculitis.

Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, Höglund P, Jayne D, Luqmani R, Mahr A, Mukhtyar C, Pusey C, Rasmussen N, Stegeman C, Walsh M, Westman K; European Vasculitis Study Group.

Ann Rheum Dis. 2011 Mar;70(3):488-94. doi: 10.1136/ard.2010.137778. Epub 2010 Nov 24.

PMID:
21109517
37.

Long-term damage to the ENT system in Wegener's granulomatosis.

Martinez Del Pero M, Walsh M, Luqmani R, Flossmann O, Mukhtyar C, Jani P, Rasmussen N, Jayne D.

Eur Arch Otorhinolaryngol. 2011 May;268(5):733-9. doi: 10.1007/s00405-010-1421-x. Epub 2010 Nov 18.

PMID:
21085976
38.

Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index.

Suppiah R, Flossman O, Mukhtyar C, Alberici F, Baslund B, Brown D, Hasan N, Holle J, Hruskova Z, Jayne D, Judge A, Little MA, Merkel PA, Palmisano A, Seo P, Stegeman C, Tesar V, Vaglio A, Westman K, Luqmani R.

Ann Rheum Dis. 2011 Jan;70(1):80-5. doi: 10.1136/ard.2009.122952. Epub 2010 Aug 24.

39.

Cardiovascular involvement in primary systemic vasculitis.

Mukhtyar C, Brogan P, Luqmani R.

Best Pract Res Clin Rheumatol. 2009 Jun;23(3):419-28. doi: 10.1016/j.berh.2009.02.002. Review.

PMID:
19508948
40.

Refractory urticarial vasculitis responsive to anti-B-cell therapy.

Mukhtyar C, Misbah S, Wilkinson J, Wordsworth P.

Br J Dermatol. 2009 Feb;160(2):470-2. doi: 10.1111/j.1365-2133.2008.08990.x. Epub 2008 Dec 11. No abstract available.

PMID:
19120327
41.

Modification and validation of the Birmingham Vasculitis Activity Score (version 3).

Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA.

Ann Rheum Dis. 2009 Dec;68(12):1827-32. doi: 10.1136/ard.2008.101279. Epub 2008 Dec 3.

PMID:
19054820
42.

EULAR recommendations for the management of primary small and medium vessel vasculitis.

Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group.

Ann Rheum Dis. 2009 Mar;68(3):310-7. doi: 10.1136/ard.2008.088096. Epub 2008 Apr 15.

43.

EULAR recommendations for the management of large vessel vasculitis.

Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R; European Vasculitis Study Group.

Ann Rheum Dis. 2009 Mar;68(3):318-23. doi: 10.1136/ard.2008.088351. Epub 2008 Apr 15.

44.

Disease-specific quality indicators, guidelines, and outcome measures in vasculitis.

Mukhtyar C, Luqmani R.

Clin Exp Rheumatol. 2007 Nov-Dec;25(6 Suppl 47):120-9. Review.

PMID:
18021517
45.

Update on the use of biologics in primary systemic vasculitides.

Mukhtyar C, Chan A, Luqmani R.

Expert Rev Clin Immunol. 2007 Nov;3(6):901-11. doi: 10.1586/1744666X.3.6.901.

PMID:
20477139
46.

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.

Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D, Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H, Luqmani RA; European Vasculitis Study Group (EUVAS).

Ann Rheum Dis. 2008 Jul;67(7):1004-10. Epub 2007 Oct 2. Review.

47.

Outpatient assessment of systemic vasculitis.

Nataraja A, Mukhtyar C, Hellmich B, Langford C, Luqmani R.

Best Pract Res Clin Rheumatol. 2007 Aug;21(4):713-32. Review.

PMID:
17678832
48.

The future of damage assessment in vasculitis.

Seo P, Luqmani RA, Flossmann O, Hellmich B, Herlyn K, Hoffman GS, Jayne D, Kallenberg CG, Langford CA, Mahr A, Matteson EL, Mukhtyar CB, Neogi T, Rutgers A, Specks U, Stone JH, Ytterberg SR, Merkel PA.

J Rheumatol. 2007 Jun;34(6):1357-71.

PMID:
17552062
49.

Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus.

Mukhtyar C, Boumpas D, Gordon C, Gross W, Jayne D, Luqmani R.

Ann Rheum Dis. 2007 May;66(5):569-70. No abstract available.

50.

Refractory Wegener's meningitis treated with rituximab.

Bawa S, Mukhtyar C, Edmonds S, Webley M.

J Rheumatol. 2007 Apr;34(4):900-1. No abstract available.

PMID:
17407257

Supplemental Content

Loading ...
Support Center